AbbVie Inc. $ABBV Shares Bought by Confluence Wealth Services Inc.

Key Points

• Confluence Wealth Services increased its AbbVie stake by 38.6% in the second quarter, owning 38,846 shares valued at approximately $9.8 million. Institutional investors collectively hold 70.23% of ABBV shares.
• Analyst sentiment remains favorable, with AbbVie receiving a consensus “Moderate Buy” rating and an average price target of $275.50; several firms recently raised their targets or upgraded the stock.
• AbbVie exceeded quarterly earnings and revenue expectations, with revenue up 10.2% year over year, and pays a $1.73 quarterly dividend. However, investors should weigh its elevated valuation and uncertainty surrounding clinical pipeline developments.

Confluence Wealth Services Inc. increased its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 38.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 38,846 shares of the company's stock after buying an additional 10,816 shares during the quarter. Confluence Wealth Services Inc.'s holdings in AbbVie were worth $9,775,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ABBV. Foundry Financial Group Inc. purchased a new stake in AbbVie in the second quarter valued at approximately $202,000. Exchange Traded Concepts LLC boosted its holdings in shares of AbbVie by 204.3% in the 2nd quarter. Exchange Traded Concepts LLC now owns 105,544 shares of the company's stock valued at $26,559,000 after purchasing an additional 70,862 shares during the last quarter. Orca Wealth Management LLC grew its stake in shares of AbbVie by 0.5% during the 2nd quarter. Orca Wealth Management LLC now owns 10,348 shares of the company's stock valued at $2,604,000 after buying an additional 49 shares during the period. Heritage Wealth Management Inc. CA acquired a new stake in shares of AbbVie during the 2nd quarter worth $234,000. Finally, Monument Capital Management raised its position in shares of AbbVie by 5.2% in the 2nd quarter. Monument Capital Management now owns 6,503 shares of the company's stock worth $1,636,000 after buying an additional 320 shares during the period. Hedge funds and other institutional investors own 70.23% of the company's stock.

Analyst Ratings Changes

Several research firms recently commented on ABBV. Weiss Ratings upgraded shares of AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a report on Tuesday, August 4th. Sanford C. Bernstein restated a "market perform" rating on shares of AbbVie in a report on Tuesday, June 23rd. Royal Bank Of Canada upped their price target on shares of AbbVie from $260.00 to $280.00 and gave the stock an "outperform" rating in a research report on Friday, July 10th. Wolfe Research upgraded AbbVie from a "peer perform" rating to an "outperform" rating and set a $300.00 price target for the company in a report on Thursday. Finally, BNP Paribas Exane raised their price objective on AbbVie from $218.00 to $247.00 and gave the company a "neutral" rating in a research report on Tuesday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, AbbVie currently has a consensus rating of "Moderate Buy" and an average target price of $275.50.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Neuroscience growth is gaining momentum: AbbVie’s neuroscience franchise delivered strong first-half growth, with Parkinson’s treatment Vyalev accelerating. Potential approval and commercialization of tavapadon could provide another growth driver in the second half of 2026. Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?
• Positive Sentiment: Post-Humira diversification remains a key bullish theme: Analysts and investors point to resilient revenue growth from AbbVie’s next-generation immunology and aesthetics portfolio. Wolfe Research upgraded AbbVie on pipeline strength and valuation, while BNP Paribas Exane also expects the stock to rise. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Positive Sentiment: Recent operating performance supports the growth case: AbbVie’s reported first-quarter 2026 revenue increased 12.4% year over year, while adjusted EPS exceeded internal expectations despite an acquired research-and-development charge. Could AbbVie Inc. Post-Humira Transformation Drive the Next Phase of Growth?
• Neutral Sentiment: Pipeline updates add potential but remain clinical-stage catalysts: AbbVie is expanding Alzheimer’s research with ABBV-1758 and studying Rinvoq against Humira in rheumatoid arthritis, while real-world China data for upadacitinib in atopic dermatitis could help reinforce Rinvoq’s commercial position. AbbVie Steps Deeper Into Alzheimer’s
• Negative Sentiment: Risks include valuation and pipeline uncertainty: A comparison with Bristol-Myers Squibb highlighted that AbbVie trades at a considerably richer valuation. Separately, the partners clarified a setback in the Phase 3 epcoritamab lymphoma study, and Erste Group Bank lowered its AbbVie earnings estimates—both potential sources of caution. Could AbbVie Win as Genmab Faces a New Regulatory Test for Epcoritamab?

AbbVie Stock Performance

ABBV opened at $249.20 on Monday. The company has a market capitalization of $440.29 billion, a P/E ratio of 70.40, a PEG ratio of 0.83 and a beta of 0.30. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47. The company has a 50-day moving average of $244.94 and a 200-day moving average of $226.16.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter last year, the business posted $2.97 EPS. AbbVie's quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts expect that AbbVie Inc. will post 14.07 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. AbbVie's dividend payout ratio (DPR) is 195.48%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source